Caitlin John LLC Makes New $361,000 Investment in Bristol Myers Squibb Company $BMY

Key Points

• Caitlin John LLC acquired 7,806 shares of Bristol Myers Squibb, valued at approximately $361,000, as part of its new position in the company during the second quarter.
• A number of hedge funds, including U.S. Capital Wealth Advisors LLC and Abound Wealth Management, significantly increased their stakes in Bristol Myers Squibb, indicating strong institutional interest in the company's stock.
• Bristol Myers Squibb reported better-than-expected earnings of $1.46 per share and revenue of $12.27 billion for the most recent quarter, exceeding analyst forecasts.

Caitlin John LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 7,806 shares of the biopharmaceutical company's stock, valued at approximately $361,000.

A number of other hedge funds also recently bought and sold shares of BMY. Pinney & Scofield Inc. purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at $26,000. Global Wealth Strategies & Associates increased its position in Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Bristol Myers Squibb in the first quarter worth about $31,000. Finally, Accent Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb during the first quarter worth about $33,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock traded down $0.04 on Monday, hitting $44.98. The company's stock had a trading volume of 11,539,880 shares, compared to its average volume of 10,775,277. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The firm has a fifty day moving average price of $46.88 and a 200-day moving average price of $49.47. The company has a market capitalization of $91.55 billion, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 2.30 and a beta of 0.35.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb's quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the business earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.5%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Analyst Ratings Changes

A number of brokerages recently commented on BMY. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Citigroup cut their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday, August 1st. Finally, Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $56.38.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.07% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.